Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has submitted an updated transparency notification to the FSMA.
The updated transparency notification has been submitted in accordance with Article 14, §4, section 2 of the royal decree of 14 November 2008 on the disclosure of large shareholdings, pursuant to which the information included in any previous transparency notification has to be updated on 31 December of each year:
(i) if assimilated financial instruments were exercised during the past calendar year, and
(ii) if assimilated financial instruments were not exercised on their expiry date without this resulting in a notification threshold being crossed downwards.
This update has been made, without any notification threshold having been crossed, with regard to certain assimilated financial instruments included in the previous transparency notification of 19 March 2014. To take into account the recent transactions of UCB SA/NV in its own shares (see the press release of 6 January 2015*, published on UCB SA/NV’s website), the transparency notification refers to the situation as per 5 January 2015.
The detailed transparency notification is available on UCB SA/NV’s website.
An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website.
* Please note that the number of UCB shares held by UCB NV/SA mentioned in the press release of 6 January 2015 (1,117,156) is incorrect: on 5 January 2015, UCB SA/NV owned 678,230 UCB shares, which represent 0.35% of the total number of shares (194,505,658).
For further information
Investor Relations, UCB
T +32.2.559.94.14, email@example.com
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 8700 people in approximately 40 countries, the company generated revenue of € 3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Forward looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.